JAK2 and acute myeloid leukemia: Additionally, activated FLT3 kinase has been identified as another molecular target for treating AML, and the concurrent inhibition of JAK2 signaling with FLT3 kinase blockade by pacritinib could enhance its clinical advantages in individuals with AML [88].